Posted by Michael Wonder on 05 Feb 2018
Ferring's Zomacton (somatropin) for injection receives FDA approval to treat growth hormone deficiency in adults
31 January 2018 - Ferring expands U.S. endocrinology portfolio.
Ferring Pharmaceuticals today announced that the U.S. FDA has approved Zomacton (somatropin) for Injection 5 mg and 10 mg recombinant human growth hormone (GH) indicated for replacement of GH in adults with GH deficiency.
In 2015, the FDA granted approval for Zomacton to be marketed in the U.S. for injection and its needle-free delivery system as ZOMA-Jet. Ferring developed and has marketed Zomacton outside of the U.S. since 1988 and in 47 countries globally.
